MAPT and Alzheimer disease: In this sense, increases in microglial reactivity [32] or, in contrast, pharmacological depletion of microglial cells [32, 36, 53, 63] clearly enhanced or reduced Alzheimer’s disease pathology, respectively, with consequent changes in tau phosphorylation, synaptic strength, and neuronal cell lost.